DUOPHARMA BIOTECH BERHAD

KLSE: 7148 (DPHARMA)

Kemas kini terakhir: 20 minit lalu

1.35

0.00 (0.00%)

Penutupan Terdahulu 1.35
Buka 1.36
Jumlah Dagangan 665,900
Purata Dagangan (3B) 709,713
Modal Pasaran 1,298,621,696
Harga / Pendapatan (P/E TTM) 16.88
Harga / Pendapatan (P/E Ke hadapan) 13.99
Harga / Jualan (P/S) 1.49
Harga / Buku (P/B) 1.85
Julat 52 Minggu
1.07 (-20%) — 1.46 (8%)
Tarikh Pendapatan 13 Aug 2025 - 18 Aug 2025
Hasil Dividen (DY TTM) 2.22%
Margin Keuntungan 8.26%
Margin Operasi (TTM) 14.69%
EPS Cair (TTM) 0.080
Pertumbuhan Hasil Suku Tahunan (YOY) 36.20%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 67.80%
Jumlah Hutang/Ekuiti (D/E MRQ) 70.73%
Nisbah Semasa (MRQ) 3.83
Aliran Tunai Operasi (OCF TTM) 114.27 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 53.91 M
Pulangan Atas Aset (ROA TTM) 5.22%
Pulangan Atas Ekuiti (ROE TTM) 10.48%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (MY) Bercampur Bercampur
Drug Manufacturers - Specialty & Generic (Global) Bercampur Bercampur
Stok DPHARMA Menaik Menaik

AISkor Stockmoo

2.0
Konsensus Penganalisis 5.0
Aktiviti Orang Dalam NA
Volatiliti Harga -1.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal 2.0
Purata 2.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
DPHARMA 1 B 2.22% 16.88 1.85
KOTRA 608 M 6.22% 13.67 2.30
YSPSAH 309 M 5.05% 12.82 0.730
RHONEMA 136 M 4.07% 15.38 0.800
PLABS 100 M - 36.50 1.20

Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 2.64%
% Dimiliki oleh Institusi 71.95%

Pemilikan

Nama Tarikh Syer Dipegang
Billion Victory Sdn Bhd 31 Mar 2023 15,070,000 (1.57%)
Manulife Investment Shariah Progress Fund 31 Oct 2022 8,670,000 (0.90%)
2.032.031.861.861.701.701.531.531.371.37Harga Sasaran MedianQ3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25Q3 '25Q3 '25
Julat 52 Minggu
1.07 (-20%) — 1.46 (8%)
Julat Harga Sasaran
1.56 (15%) — 1.70 (25%)
Tinggi 1.70 (TA, 25.93%) Beli
Median 1.63 (20.74%)
Rendah 1.56 (RHB, 15.56%) Beli
Purata 1.63 (20.74%)
Jumlah 2 Beli
Harga Purata @ Panggilan 1.37
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
TA 03 Jul 2025 1.70 (25.93%) Beli 1.35
21 May 2025 1.70 (25.93%) Beli 1.32
RHB 06 Jun 2025 1.56 (15.56%) Beli 1.38
16 May 2025 1.50 (11.11%) Beli 1.29

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
16 Jun 2025 Pengumuman Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
06 Jun 2025 TheEdge Duopharma's sales to public sector could moderate in coming months, Kenanga says
06 Jun 2025 TheEdge UOB Kay Hian cuts earnings, keeps FBM KLCI target at 1,620 on 2H2025 recovery hopes
04 Jun 2025 TheEdge Kenanga lowers KLCI’s end-2025 target to 1,655, halves earnings forecast after weak 1Q
29 May 2025 Pengumuman Change in Boardroom - DR HASNITA BINTI HASHIM
29 May 2025 Pengumuman CHANGE IN THE STRUCTURE AND COMPOSITION OF THE BOARD COMMITTEES OF DUOPHARMA BIOTECH BERHAD
29 May 2025 Pengumuman Change in Audit Committee - DR HASNITA BINTI HASHIM
23 May 2025 Pengumuman Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
22 May 2025 Pengumuman Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
21 May 2025 TheSun Duopharma eyes Indonesia for halal product growth
21 May 2025 TheEdge Duopharma sees stronger halal product demand from Indonesia amid policy support
21 May 2025 TheSun Duopharma Biotech targets more halal exports to Indonesia
21 May 2025 Pengumuman Change in Boardroom - DATUK WIRA ARHAM BIN ABDUL RAHMAN
21 May 2025 Pengumuman Change in Boardroom - DATO ADNAN HISHAM BIN PAWANTEH
21 May 2025 Pengumuman Change in Boardroom - DR SHARMILA A/P RAMACHANDRAN
21 May 2025 Pengumuman Change in Audit Committee - ENCIK RAZALEE BIN AMIN
21 May 2025 Pengumuman Change in Audit Committee - PUAN NIK FAZILA BINTI NIK MOHAMED SHIHABUDDIN
21 May 2025 Pengumuman Change in Audit Committee - PUAN ZAITON BINTI JAMALUDDIN
21 May 2025 Pengumuman Change in Audit Committee - DR SHARMILA A/P RAMACHANDRAN
21 May 2025 Pengumuman Change in Nomination and Remuneration Committee - DATUK WIRA ARHAM BIN ABDUL RAHMAN
21 May 2025 Pengumuman Change in Nomination and Remuneration Committee - DATO' DR ZAKI MORAD BIN MOHAMAD ZAHER
21 May 2025 Pengumuman Change in Risk Committee - DATUK MOHD RADZIF BIN MOHD YUNUS
21 May 2025 Pengumuman Change in Risk Committee - PUAN ZAITON BINTI JAMALUDDIN
21 May 2025 Pengumuman Change in Risk Committee - DATUK NIK MOUSTPHA BIN HAJI NIK HASSAN
21 May 2025 Pengumuman Change in Risk Committee - DATUK WIRA ARHAM BIN ABDUL RAHMAN
21 May 2025 Pengumuman Change in Risk Committee - DR SHARMILA A/P RAMACHANDRAN
21 May 2025 Pengumuman CHANGE IN THE STRUCTURE AND COMPOSITION OF THE BOARD COMMITTEES OF DUOPHARMA BIOTECH BERHAD
21 May 2025 Pengumuman General Meetings: Outcome of Meeting
21 May 2025 Pengumuman Change in Boardroom - DATO' DR ZAKI MORAD BIN MOHAMAD ZAHER
21 May 2025 Pengumuman Change in Boardroom - ENCIK RAZALEE BIN AMIN
21 May 2025 Pengumuman Change in Boardroom - PUAN ZAITON BINTI JAMALUDDIN
21 May 2025 Pengumuman Change in Boardroom - DATUK NIK MOUSTPHA BIN HAJI NIK HASSAN
21 May 2025 Pengumuman Duopharma Biotech Maintains Focus on Domestic Market Leadership and International Growth
21 May 2025 Pengumuman Change in Risk Committee - DATO' EISAH BINTI A. RAHMAN
20 May 2025 TheEdge MOH grants Duopharma six-month contract extension for insulin supply
20 May 2025 Pengumuman AGREEMENT FOR THE PROCUREMENT VIA DIRECT NEGOTIATION FOR THE SUPPLY OF INSULIN MEDICINE AS A PACKAGE ('PERJANJIAN PEROLEHAN SECARA RUNDINGAN TERUS PEMBEKALAN UBAT INSULIN RECOMBINANT HUMAN 100IU/ML PENFILL/REFILL SECARA PAKEJ') PURSUANT TO THE ACCEPTANCE OF TENDER OFFER FOR THE SUPPLY OF RECOMBINANT HUMAN INSULIN FORMULATIONS (HEREINAFTER REFERRED TO AS THE "PRODUCTS") TO THE GOVERNMENT OF MALAYSIA
20 May 2025 Pengumuman Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
19 May 2025 Pengumuman MATERIAL LITIGATION
15 May 2025 TheEdge Duopharma posts record-high 1Q profit on strong sales, active ingredient price normalisation
15 May 2025 Pengumuman Quarterly rpt on consolidated results for the financial period ended 31/03/2025
15 May 2025 Pengumuman Duopharma Biotech Records 36.2% Revenue Growth and 67.8% Profit Improvement in Q1 FY2025
15 May 2025 Pengumuman Revised Administrative Guide
14 May 2025 Pengumuman Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
13 May 2025 Pengumuman Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
13 May 2025 TheEdge Duopharma set for strong 1Q growth backed by approved products purchase list contracts — CGS International
28 Apr 2025 TheEdge Nestlé Malaysia, Bursa Malaysia, BAT Malaysia, F&N, Rohas Tecnic, MKH, Meta Bright, Duopharma Biotech, Pintaras Jaya, Johor Plantations
28 Apr 2025 TheEdge Duopharma bags another supply contract from Pharmaniaga
28 Apr 2025 TheEdge Dividend stocks regain appeal as global uncertainty looms
28 Apr 2025 Pengumuman CONTRACTS FOR THE SUPPLY BY DUOPHARMA (M) SENDIRIAN BERHAD, DUOPHARMA MANUFACTURING (BANGI) SDN. BHD. AND DUOPHARMA HAPI SDN. BHD. (ALL WHOLLY-OWNED SUBSIDIARY COMPANIES OF DUOPHARMA BIOTECH BERHAD), THROUGH PHARMANIAGA LOGISTICS SDN. BHD. OF PHARMACEUTICAL AND/OR NON-PHARMACEUTICAL PRODUCTS FOR THE MINISTRY OF HEALTH OF MALAYSIA UNDER THE APPROVED PRODUCTS PURCHASE LIST (Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhad Main Market Listing Requirements)
21 Apr 2025 Pengumuman Annual Audited Accounts - 31 Dec 2024
21 Apr 2025 Pengumuman Annual Report & CG Report - 2024
18 Apr 2025 Pengumuman General Meetings: Notice of Meeting
17 Apr 2025 TheEdge Cover Story: Healing old wounds and growing new income streams at Pharmaniaga
10 Apr 2025 TheEdge Cover Story: Risk-off mode likely to continue in 2Q on continuous foreign fund outflows
09 Apr 2025 Pengumuman CONTRACT FOR THE SUPPLY BY DUOPHARMA HAPI SDN. BHD. (A WHOLLY-OWNED SUBSIDIARY COMPANY OF DUOPHARMA BIOTECH BERHAD), THROUGH PHARMANIAGA LOGISTICS SDN. BHD. OF PHARMACEUTICAL AND/OR NON-PHARMACEUTICAL PRODUCTS FOR THE MINISTRY OF HEALTH OF MALAYSIA UNDER THE APPROVED PRODUCTS PURCHASE LIST (Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhad Main Market Listing Requirements)
09 Apr 2025 TheEdge Duopharma Biotech bags supply contracts worth RM16.58m from govt in third round of award
Papar semua
Hasil Dividen (DY TTM) 2.22%
Purata Hasil Dividen 5T 2.31%
Nisbah Pembayaran 39.53%
Jangkaan Pembayaran Dividen Seterusnya Sep 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
05 Mar 2025 19 Feb 2025 19 Mar 2025 0.02 Tunai
29 Aug 2024 15 Aug 2024 12 Sep 2024 0.01 Tunai
07 Mar 2024 22 Feb 2024 21 Mar 2024 0.018 Tunai
08 Sep 2023 24 Aug 2023 22 Sep 2023 0.005 Tunai
07 Apr 2023 27 Mar 2023 09 May 2023 0.018 Tunai
29 Aug 2022 16 Aug 2022 14 Sep 2022 0.005 Tunai
14 Apr 2022 24 Mar 2022 13 May 2022 0.018 Tunai
30 Aug 2021 17 Aug 2021 15 Sep 2021 0.005 Tunai
21 Apr 2021 08 Apr 2021 21 May 2021 0.06 Tunai
28 Aug 2020 13 Aug 2020 11 Sep 2020 0.005 Tunai
13 Jul 2020 30 Jun 2020 12 Aug 2020 0.05 Tunai
15 Oct 2019 02 Oct 2019 14 Nov 2019 0.01 Tunai
26 Jun 2019 13 Jun 2019 26 Jul 2019 0.04 Tunai
02 Nov 2018 22 Oct 2018 23 Nov 2018 0.015 Tunai
13 Jun 2018 31 May 2018 17 Jul 2018 0.06 Tunai
17 Oct 2017 25 Aug 2017 10 Nov 2017 0.025 Tunai
26 May 2017 24 Feb 2017 23 Jun 2017 0.04 Tunai
19 Oct 2016 22 Aug 2016 11 Nov 2016 0.025 Tunai
06 Jun 2016 23 Feb 2016 28 Jun 2016 0.055 Tunai
13 Oct 2015 25 Aug 2015 06 Nov 2015 0.04 Tunai
27 May 2015 24 Feb 2015 25 Jun 2015 0.145 Tunai
15 Oct 2014 26 Aug 2014 07 Nov 2014 0.04 Tunai
22 May 2014 26 Feb 2014 20 Jun 2014 0.135 Tunai
14 Oct 2013 28 Aug 2013 08 Nov 2013 0.04 Tunai
14 Jun 2013 22 Mar 2013 12 Jul 2013 0.105 Tunai
15 Oct 2012 16 Aug 2012 09 Nov 2012 0.035 Tunai
06 Jun 2012 16 Mar 2012 29 Jun 2012 0.145 Tunai
05 Oct 2011 18 Aug 2011 28 Oct 2011 0.035 Tunai
08 Jun 2011 21 Apr 2011 27 Jun 2011 0.11 Tunai
06 Oct 2010 02 Sep 2010 28 Oct 2010 0.045 Tunai
09 Jun 2010 21 Apr 2010 25 Jun 2010 0.12 Tunai
01 Oct 2009 26 Aug 2009 23 Oct 2009 0.06 Tunai
10 Jun 2009 15 Apr 2009 26 Jun 2009 0.07 Tunai
08 Oct 2008 26 Aug 2008 28 Oct 2008 Interim Dividend
03 Oct 2007 24 Aug 2007 18 Oct 2007 Interim Dividend
29 May 2007 25 Apr 2007 08 Jun 2007 Final Dividend
11 Sep 2006 23 Aug 2006 22 Sep 2006 Interim Dividend
18 May 2006 24 Apr 2006 08 Jun 2006 First and Final Dividend
26 Jul 2005 06 Jun 2005 18 Aug 2005 Final Dividend
21 Oct 2004 06 Oct 2004 08 Nov 2004 Interim Dividend
06 Jul 2004 01 Jun 2004 28 Jul 2004 Final Dividend
26 Sep 2003 09 Sep 2003 20 Oct 2003 Interim Dividend
23 Jun 2003 25 Apr 2003 08 Jul 2003 First and Final Dividend
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 0.020 1 1.48
2024 0.028 2 2.24
2023 0.023 2 1.83
2022 0.023 2 1.43
2021 0.065 2 3.87
2020 0.055 2 2.17
2019 0.050 2 4.70
2018 0.075 2 10.53
2017 0.065 2 7.99
2016 0.080 2 12.57
2015 0.185 2 21.97
2014 0.175 2 29.38
2013 0.145 2 23.59
2012 0.180 2 35.47
2011 0.145 2 30.13
2010 0.165 2 28.97
2009 0.130 2 23.22
Papar semua
1.401.401.371.371.331.331.301.301.271.27Jun 24Jun 24Jun 25Jun 25Jun 26Jun 26Jun 30Jun 30Jul 1Jul 1Jul 2Jul 2Jul 3Jul 3Jul 4Jul 4

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0400.0400.0300.0300.0200.0200.0100.0100.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda